Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non–Small Cell Lung Cancer Cells

Crizotinib is the first anaplastic lymphoma kinase (ALK) inhibitor to have been approved for the treatment of non–small cell lung cancer (NSCLC) harboring an ALK fusion gene, but it has been found that, in the clinic, patients develop resistance to it. Alectinib and ceritinib are second-generation A...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Xuyuan, Fernandez-Salas, Ester, Li, Enxiao, Wang, Shaomeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796802/
https://www.ncbi.nlm.nih.gov/pubmed/26992917
http://dx.doi.org/10.1016/j.neo.2016.02.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796802/
https://www.ncbi.nlm.nih.gov/pubmed/26992917
http://dx.doi.org/10.1016/j.neo.2016.02.001

Ejemplares similares